NS-089/NCNP-02 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 2 |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05135663 (ClinicalTrials.gov) | June 23, 2021 | 5/10/2021 | Extension Study of NS-089/NCNP-02 in DMD | A Phase II, Open-Label, Extension Study of NS-089/NCNP-02 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy (DMD) | Drug: NS-089/NCNP-02 | Nippon Shinyaku Co., Ltd. | NULL | Active, not recruiting | N/A | N/A | Male | 6 | Phase 2 | Japan |
| 2 | NCT04129294 (ClinicalTrials.gov) | December 2, 2019 | 15/10/2019 | Exploratory Study of NS-089/NCNP-02 in DMD | Exploratory Study of NS-089/NCNP-02 in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: NS-089/NCNP-02 | National Center of Neurology and Psychiatry, Japan | Nippon Shinyaku Co., Ltd. | Completed | 4 Years | 17 Years | Male | 6 | Phase 1/Phase 2 | Japan |